)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Aldeyra Therapeutics
Aldeyra Therapeutics (ALDX) investor relations material
Aldeyra Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary5 Nov, 2026
Executive summary
Q3 2026 net loss narrowed to $3.8M from $7.7M YoY, mainly reflecting lower R&D spending; no product sales revenue is currently generated.
Reproxalap remains the key late-stage asset: a formal dispute resolution request (FDRR) appealing the FDA’s 2026 Complete Response Letter was filed Oct. 26; an OND meeting is expected in Q4 2026.
Financial highlights
Q3 R&D expense was $1.8M vs. $5.4M YoY; G&A was $2.3M vs. $2.6M, reducing operating loss to $4.1M from $8.0M.
Q3 net loss was $3.8M vs. $7.7M YoY; basic and diluted loss per share was $0.06 vs. $0.13.
9M R&D expense was $7.7M vs. $21.4M YoY; G&A was $5.8M vs. $7.2M, and operating loss was $13.5M vs. $28.6M.
9M net loss was $12.7M vs. $27.4M YoY; basic and diluted loss per share was $0.21 vs. $0.46.
Outlook and guidance
Current operating plan projects cash sufficiency into 2029, excluding potential licensing and product revenue; projections depend on assumptions and additional funding will be needed for planned activities.
R&D spending is expected to increase as ADX-248, ADX-246 and other candidates advance; future costs and timelines depend on clinical results, FDA feedback, recruitment and funding.
Additional pipeline guidance is expected after resolution of the reproxalap FDRR; OND discussions are expected during Q4 2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Aldeyra Therapeutics
- Formal dispute resolution request for reproxalap in dry eye disease to be reviewed by FDA in Q4 2026.ALDX
FDA announcement - Net loss narrowed on lower R&D costs, but regulatory delays for reproxalap persist.ALDXQ2 2026
- NDA resubmission for reproxalap in dry eye disease is planned after strong new trial results.ALDXJefferies Global Healthcare Conference 2025
- Reproxalap nears FDA decision as a rapid-acting dry eye therapy, with major 2025 milestones ahead.ALDXJefferies London Healthcare Conference 2024
- Reproxalap approaches FDA approval with a robust pipeline advancing in immunology and retina.ALDXLeerink’s Global Healthcare Conference 2025
- Late-stage dry eye program nears key FDA decision, with strong cash and AbbVie partnership.ALDXJefferies Global Healthcare Conference 2026
- RASP platform expands into CNS, with ADX-248 and reproxalap advancing toward key milestones.ALDXR&D Day 2025
- Reproxalap achieved rapid, significant symptom relief in Phase 3 trial, enabling 2024 NDA resubmission.ALDXStudy Update
- FDA requests more efficacy data for reproxalap; NDA resubmission targeted for mid-2025.ALDXStatus Update
Next Aldeyra Therapeutics earnings date
Q4 202626 Feb, 2027
Aldeyra Therapeutics
Next Aldeyra Therapeutics earnings date
Q4 202626 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Aldeyra Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for immune-mediated diseases. The company is engaged in advancing its pipeline of drug candidates, which target diseases caused by inflammation and tissue damage. Aldeyra's approach is centered on modulating immune responses to treat conditions such as ocular and systemic inflammatory diseases. Its lead therapeutic areas include ophthalmology, with treatments aimed at conditions like dry eye disease and allergic conjunctivitis. The company's goal is to provide new treatment options for diseases with limited or inadequate therapies. The company is headquartered in Lexington, Massachusetts, and its shares are listed on the NASDAQ.